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Abstract
Background: We have previously shown that the Gene expression Grade Index (GGI) was able
to identify two subtypes of estrogen receptor (ER)-positive tumors that were associated with
statistically distinct clinical outcomes in both untreated and tamoxifen-treated patients. Here, we
aim to investigate the ability of the GGI to predict relapses in postmenopausal women who were
treated with tamoxifen (T) or letrozole (L) within the BIG 1–98 trial.
Methods: We generated gene expression profiles (Affymetrix) and computed the GGI for a
matched, case-control sample of patients enrolled in the BIG 1–98 trial from the two hospitals
where frozen samples were available. All relapses (cases) were identified from patients randomized
to receive monotherapy or from the switching treatment arms for whom relapse occurred before
the switch. Each case was randomly matched with four controls based upon nodal status and
treatment (T or L). The prognostic value of GGI was assessed as a continuous predictor and
divided at the median. Predictive accuracy of GGI was estimated using time-dependent area under
the curve (AUC) of the ROC curves.
Results: Frozen samples were analyzable for 48 patients (10 cases and 38 controls). Seven of the
10 cases had been assigned to receive L. Cases and controls were comparable with respect to
menopausal and nodal status, local and chemotherapy, and HER2 positivity. Cases were slightly
older than controls and had a larger proportion of large, poorly differentiated ER+/PgR- tumors.
The GGI was significantly and linearly related to risk of relapse: each 10-unit increase in GGI
resulted in an increase of approximately 11% in the hazard rate (p = 0.02). Within the subgroups
of patients with node-positive disease or who were treated with L, the hazard of relapse was
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significantly greater for patients with GGI at or above the median. AUC reached a maximum of 78%
at 27 months.
Conclusion:  This analysis supports the GGI as a good predictor of relapse for ER-positive
patients, even among patients who receive L. Validation of these results, in a larger series from BIG
1–98, is planned using the simplified GGI represented by a smaller set of genes and tested by qRT-
PCR on paraffin-embedded tissues.
Background
Most breast cancer patients whose tumors express the
estrogen receptor (ER) receive endocrine therapy. Despite
ER status being one of the most reliable biomarkers used
today to predict response to endocrine therapy, such as
tamoxifen or an aromatase inhibitor, a significant propor-
tion of women still relapse, which indicates the need for
additional predictive markers.
Several studies have reported that breast cancer is a molec-
ularly heterogeneous disease and that distinct gene
expression patterns are particularly evident in women
within the subgroup of ER-positive breast cancers
(reviewed in [1]). These studies have consistently shown,
on the basis of hierarchical clustering of gene expression
profiles, that ER-positive breast cancers can be classified
into molecular subtypes (mainly luminal A and B) and
that these subtypes are associated with a different clinical
outcome, suggesting a molecular basis behind the clinical
heterogeneity. Unfortunately, the classifications gener-
ated by this cluster analysis are at present not useful for
the clinical setting, since there is currently no operational
definition of what constitutes each luminal subtype.
Our group recently developed a Gene expression Grade
Index (GGI) score based on 97 genes mainly involved in
cell cycle regulation, proliferation and differentiation and
consistently differentially expressed between low and
high grade breast carcinomas [2]. Interestingly, the GGI
was not only able to reclassify patients with histological
grade 2 tumors into two groups with distinct clinical out-
comes similar to those of histological grade 1 and 3, but
also to define two molecular subgroups within ER-posi-
tive breast cancers, in a reproducible and quantitative
manner, that were highly comparable to the previously
described luminal A and B classification [3]. Indeed, the
samples previously classified as luminal A or B were asso-
ciated with significantly different GGI values across the
different populations evaluated, with all of the ER-posi-
tive luminal A subtypes, which had the best clinical out-
come, being associated with low GGI values and the
luminal B tumors having significantly higher GGI values.
We also showed that these two subtypes were associated
with statistically distinct clinical outcome in both system-
ically untreated and tamoxifen-treated populations.
Given these results, it appeared crucial to understand
whether patients with a high GGI would benefit from
alternative anti-estrogen agents, such as aromatase inhib-
itors, which have globally shown superiority over
tamoxifen [4-8] or would need a completely different
treatment strategy. Thus, we aimed to investigate the abil-
ity of the GGI to predict relapses in postmenopausal
women with hormone receptor-positive breast cancer
who were treated with tamoxifen (T) or letrozole (L)
within the BIG 1–98 trial.
Methods
Patients
The design and conduct of the BIG 1–98 study have been
described elsewhere [9]. Briefly, the BIG 1–98 trial con-
sists of four treatment groups that compare 5 years of
monotherapy with letrozole (L) or tamoxifen (T), and
sequential administration of one drug for 2 years followed
by the other drug for 3 years. Patients with cancer relapse
from sites with available frozen material, needed for gene
expression profiling, were identified from the BIG 1–98
database (version of February 2007). Only two Belgian
sites had frozen material. Relapses (cases) were defined as
either local, contra-lateral breast, regional, distant soft tis-
sue, bone, or distant viscera and were identified from
patients randomized to receive either monotherapy or
from the switching treatment arms for whom relapse
occurred before the switch. There were 14 patients with
relapse from these two hospitals. Each was randomly
matched with four controls based upon nodal status (neg-
ative (N-/Nx) or positive (N+)) and treatment (T or L),
resulting in a listing of 70 patients. The investigators
received only a list of patient identification numbers with
no additional information. This study was approved by
the BIG 1–98 Steering Committee and by the local ethics
committee.
Gene expression analysis
Frozen samples from the cases and controls selected by
the International Breast Cancer Study Group (IBCSG) Sta-
tistical Center were collected in the two hospitals and sent
to the Translational Research Unit from the Institut Jules
Bordet where the samples were further processed. Isola-
tion of RNA was performed using the Trizol method (Inv-
itrogen) according to the manufacturer's instructions and
purified using RNeasy mini-columns (Qiagen, Valencia,
CA). The quality of the RNA obtained from each tumorBMC Medical Genomics 2009, 2:40 http://www.biomedcentral.com/1755-8794/2/40
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sample was assessed based on the RNA profile generated
by the bioanalyzer (Agilent Inc). RNA amplification,
hybridization and image scanning were done according to
standard Affymetrix protocols. We used the Affymetrix
Human Genome U133-2.0 plus GeneChip, which con-
tains almost 50,000 probe sets representing more than
47,000 transcripts, derived from approximately 39,500
well-substantiated human genes. The GGI scores were
defined as in Sotiriou et al. [2] by the Institut Jules Bordet,
blinded to the clinical data, and sent to the IBCSG statis-
tical office. The raw gene expression data, together with
the patient's characteristics are publicly available on GEO
http://www.ncbi.nlm.nih.gov/geo, with accession
number GSE16391.
Pathology
The IBCSG Central Pathology Laboratory performed cen-
tral review of paraffin-embedded primary tumor speci-
mens for HER2 by IHC and fluorescence in-situ
hybridization (FISH) [10]. Tumors were considered to be
HER2-positive if amplified by FISH, or in a few cases with
unevaluable FISH results, if IHC = 3+.
Statistical analyses
Cases and controls were compared descriptively based
upon demographics (menopausal status, age), tumor
characteristics (tumor size and grade, nodal status, ER/
PgR status, HER2 positivity), therapy received (breast-con-
serving surgery, mastectomy, radiotherapy, adjuvant or
neoadjuvant chemotherapy), length of follow-up, and
GGI. Comparisons of disease and demographic character-
istics at baseline were conducted using Wilcoxon rank-
sum tests for continuous variables and Fisher's exact test
for categorical variables. Data analysis was based on Kap-
lan-Meier estimation and general principles of the Cox
model. To evaluate the independent prognostic value of
the GGI, multivariable proportional hazards regression
models were employed. Models were stratified by combi-
nations of the matching criteria, nodal status and treat-
ment, and results reported using hazard ratios with 95%
confidence intervals. Multivariable proportional hazards
regression was also used to explore the prognostic value of
GGI within subgroups defined by treatment or nodal sta-
tus. Performance of the GGI was summarized as a contin-
uous predictor and divided at the median
To assess the predictive accuracy of the GGI, time-depend-
ent sensitivity and specificity and time-dependent ROC
and AUC curves were constructed using the incident/
dynamic definitions of Heagerty and Zheng [11]. The
areas under the time-specific ROC curves, AUC(t), were
plotted as a function of time to characterize temporal
changes in accuracy of the GGI marker. An R/S-plus pack-
age, risksetROC, was used to handle the computations
and was available for download through Dr. Heagerty's
website [12].
All the statistical analyses were performed by the IBCSG
Statistical Center (AG-H and RDG).
Results
Description of the study population
Frozen tissue was available and analyzable for 48 patients
out of the original list of 70 (see methods for selection
procedure), 10 cases (relapses) and 38 controls (non-
relapses). Due to the limited amount of available tissue,
samples from controls that did not have results from their
original matched case were paired, where applicable, with
another case having the same matching characteristics.
Five controls were reassigned and resulted in two cases
each matched with 6 controls and one case matched with
five. Controls were reassigned before any analyses or data
comparisons were conducted. Table 1 summarizes the
number of relapses and matching criteria for samples with
GGI. Five patients with relapse (50%) had tumors in the
distant viscera, two (20%) recurred in the bone, two
(20%) had contra-lateral breast cancer, and one (10%)
had a local recurrence. The median time to relapse among
cases was 23.8 months [range: 11 to 49 months].
Tables 2 and 3 summarize the demographic and tumor
characteristics of cases and controls. Cases and controls
were comparable with respect to menopausal status,
nodal status, local therapy, HER2 positivity, and adjuvant
or neoadjuvant chemotherapy. Cases were slightly older
than controls, with median ages of 62.5 years and 59
years, respectively. A larger proportion of cases had grade-
3 tumors, tumors above 2 cm, and ER-positive/PgR-nega-
tive disease (locally assessed). Seven of the cases were ran-
domized to receive L. Median GGI in cases was 785
compared with 669 for controls. Overall median follow-
up time, based upon Kaplan-Meier estimates, was 27.9
months [range: 11 to 66 months].
Overall effect of the Genomic Grade on the hazard of 
relapse
To estimate the overall effect of GGI upon hazard of
relapse, a Cox model, stratified by the four combinations
Table 1: Relapse status by nodal status and treatment for which 
frozen samples and GGI score were available.
Relapse (Cases) No relapse (Controls) Total
N-/Nx, L 39 1 2
N-/Nx, T 15 6
N+, L 41 2 1 6
N+, T 21 2 1 4
Total 10 38 48
N-: node-negative; N+: node-positive; Nx: unknown nodal status. L: 
letrozole and T: tamoxifenBMC Medical Genomics 2009, 2:40 http://www.biomedcentral.com/1755-8794/2/40
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Table 2: Univariate comparisons of baseline characteristics.
Case/Control
Case Control Overall
Characteristic N (%) N (%) N P-value*
Menopausal category
Postmen. before chemo 9 90.0 34 89.5 43
Postmen. after chemo 1 10.0 4 10.5 5 0.99
Tumor size
£   2 cm 1 10.0 15 39.5 16
> 2 cm 9 90.0 23 60.6 32 0.13
Tumor grade ..
Grade 1 25 . 3 2
Grade 2 3 30.0 27 71.1 30
Grade 3 7 70.0 9 23.7 16 0.03
Nodal status
N-/Nx 4 40.0 14 36.8 18
N+ 6 60.0 24 63.2 30 0.99
ER and PgR status
ER-pos/PgR-pos 5 50.0 33 86.8 38
ER-pos/PgR-neg 5 50.0 5 13.2 10 0.02
HER2 Positive
No 8 80.0 29 76.3 37
Yes 1 10.0 1 2.6 2
Unknown 1 10.0 8 21.0 9 0.41
Local therapy
BCS and radiotherapy 55 0 .  0 2 46 3 . 2 2 9
BCS and no radiotherapy .. 1 2 . 6 1
Mastectomy and radiotherapy 44 0 . 0 9 2 3 . 7 1 3
Mastectomy and no radiotherapy 1 10.0 4 10.5 5 0.73BMC Medical Genomics 2009, 2:40 http://www.biomedcentral.com/1755-8794/2/40
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of treatment and nodal status, was employed with the
GGI as a continuous, linear predictor. The GGI was signif-
icantly and linearly related to risk of relapse: each 10-unit
increase in GGI resulted in an increase of approximately
11% in the hazard rate (95% CI 3% to 21%, log-rank p-
value = 0.02).
Since there is no defined cutoff to classify the samples into
high and low GGI categories, we considered the median
value (683.2) as the cut point. The hazard of a relapse for
patients with high GGI was not statistically different from
the hazard with low GGI (hazard ratio: 4.55, 95% CI 0.95
to 21.7, log-rank p-value = 0.06), although the probability
is small enough to provide evidence that there is a rela-
tionship between GGI classification (when divided at the
median GGI value) and relapse.
Effect of the Genomic Grade on the hazard of relapse 
according to follow-up time
The prognostic potential of the GGI was assessed using
Cox proportional hazards regression with GGI as the sin-
gle covariate to estimate time-specific ROC curves. ROC
curves were constructed for times between 0 and 50
months and the areas under the ROC curves were then
plotted to obtain the AUC(t) function (100% = perfect
classification, 50% = no discrimination). Estimates of
AUC(t) are shown in Figure 1. Over the first 24 months of
follow-up, the AUC(t) ranged between 73% and 74%.
This may be interpreted to say that for any time, t, between
0 and 24 months, the probability was at least 73% that a
patient who relapsed at time t had a GGI score greater
than a patient who had not relapsed at time t. AUC(t)
reached a maximum value of 77.6% at 27 months, with
maximal discrimination occurring at approximately the
median follow-up time observed in the data.
Figure 2 shows ROC curves at 24, 27, 36, and 48 months
based on GGI. The ROC curves also show that predictive
accuracy peaks at approximately 27 months and then
decreases with increasing time from baseline. The ROC
curves may be used to compare the sensitivities resulting
from a fixed false-positive rate. For example, controlling
the false-positive rate at 20% leads to a sensitivity of
55.5% at 24 months, 56% at 27 months, and 54% and
43% at 36 and 48 months, respectively. Table 4 summa-
rizes true- and false-positive rates for the GGI divided at
the median at 24, 27, 36 and 48 months after enrollment.
The accuracy summaries (AUC) suggest good discrimina-
tory potential of the GGI within 36 months of enrollment,
with the best discrimination occurring near the median
follow time.
Effect of the Genomic Grade on the hazard of relapse 
according to treatment
To estimate the effect of GGI upon relapse for each treat-
ment assignment, exploratory subgroup comparisons of
Adjuvant or neoadjuvant chemo
No 6 60.0 24 63.2 30
Yes 4 40.0 14 36.8 18 0.99
Treatment
Letrozole 7 70.0 21 55.3 28
Tamoxifen 3 30.0 17 44.7 20 0.49
*Fisher's exact p-value
Table 2: Univariate comparisons of baseline characteristics. (Continued)
Table 3: Univariate comparisons of other prognostic factors.
Case/Control
Case Control Overall
Median Min Max Median Min Max Median Min Max P-value*
Age at randomization 62.5 52 70 59 46 78 59.5 46 78 0.81
GGI 785.10 584.95 854.21 668.91 550.03 872.28 683.23 550.03 872.28 0.02
*Wilcoxon rank-sumBMC Medical Genomics 2009, 2:40 http://www.biomedcentral.com/1755-8794/2/40
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times to relapse according to GGI were made separately
for letrozole and tamoxifen. For patients randomized to
receive L, the hazard of relapse in the patients with GGI
above the median was 4.8 times the hazard of patients
with GGI below (95% CI: 1.01 to 22.9, p = 0.048). With
only 3 cases in the sample receiving T, there was no evi-
dence of a difference in the risk of relapse in that treat-
ment group between high and low GGI.
Effect of the Genomic Grade on the hazard of relapse 
according to the nodal status
To estimate the effect of GGI upon relapse for each nodal
status, comparisons of times to relapse according to GGI
were made separately for subgroups defined by N+ and
Nx/N-. For patients with node-positive disease, the hazard
of relapse in the patients with GGI above the median was
5.5 times the hazard of patients with GGI below (95% CI:
1.12 to 26.9, p = 0.04). There was no evidence of a differ-
ence in the risk of relapse between high and low GGI for
patients with node-negative disease, which might be
explained by the small number of node-negative cases.
Discussion
The efficacy of aromatase inhibitors in treating hormone-
dependent breast cancer patients has been demonstrated
in several clinical trials, where a significant increase in dis-
ease-free survival has been shown using third-generation
aromatase inhibitors [4-8,13]. However, as with
tamoxifen, resistance to these therapies does develop and
patients recur. We recently showed that tamoxifen-treated
patients whose tumors were of high genomic grade were
associated with a worse outcome than those with a low
GGI. However, since the actions of tamoxifen (ER antago-
nist) and aromatase inhibitors (prevention of estrogen
synthesis) are inherently different, we sought in this study
to assess whether high GGI levels would also be associated
with worse outcome in patients treated with aromatase
inhibitors.
Altogether, these results confirm our previous findings,
i.e. that the GGI is a good predictor of relapse in ER-posi-
tive breast cancer patients [3]. Indeed, this analysis sup-
ports the GGI as a good predictor of relapse in the sample
of 48 postmenopausal patients with hormone-positive
breast cancer of the prospective BIG 1–98 trial with avail-
able frozen tissue and suggests that higher values of the
GGI are associated with an increase in the hazard of a
relapse, with each 10-unit increase in GGI resulting in an
approximate 11% increase in the hazard rate. Also consid-
ering the GGI as a binary variable defined by the median
value, provided evidence for a relationship between high
GGI values and increase risk of relapse. Using time-
dependent, incident/dynamic, ROC/AUC methodology,
estimated AUC values between 73% and 78%, occurring
during the first 36 months of enrollment, suggest that the
GGI has good predictive ability for relapse, with the best
predictive ability occurring at approximately 27 months.
However, false-positive rates using the GGI were high,
remaining above 40%.
Exploratory subgroup analyses within nodal status or
treatment suggest that high values of GGI indicate worse
outcomes. When the performance of GGI was compared
within nodal status, the hazard of relapse was significantly
greater for patients with GGI at or above the median
within the subgroup of patients with node-positive dis-
ease.
The predictive accuracy of the GGI estimated using time- dependent area under the curve (AUC) of the ROC curves Figure 1
The predictive accuracy of the GGI estimated using 
time-dependent area under the curve (AUC) of the 
ROC curves.
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Table 4: Summary of Estimated True- and False-positive Rates over Time.
GGI value (%-ile) 24 Months 27 Months 36 Months 48 Months
TP rate FP rate TP rate FP rate TP rate FP rate TP rate FP rate
median 0.82 0.50 0.79 0.41 0.78 0.45 0.68 0.42
AUC 0.74 0.776 0.73 0.68
TP = True-positive; FP = False-positiveBMC Medical Genomics 2009, 2:40 http://www.biomedcentral.com/1755-8794/2/40
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Analyses of GGI performance within treatment assign-
ment were somewhat limited, due to the small number of
cases with available samples for patients treated with
tamoxifen. Within the subgroup of patients randomized
to treatment with letrozole, the hazard of relapse was sig-
nificantly greater for patients with GGI at or above the
median when compared to patients with GGI values
below.
Conclusion
These results, together with our previous retrospective
data on tamoxifen-treated patients, suggest that the ER-
positive high-genomic grade patients would require
another treatment strategy.
Although very promising, our results are exploratory and
need to be confirmed. This is planned on a larger number
of samples from this same BIG 1–98 trial using the simpli-
fied GGI, which is represented by only four genes and can
be tested by RT-PCR on formalin-fixed paraffin-embed-
ded tissues (FFPE) that, in contrast to frozen samples, are
routinely available in all hospitals. We will then also be
able to investigate whether, as reported recently by Viale
et al. on 2685 women from this same trial [14], highly
proliferative tumors, captured in their study by Ki-67 pro-
tein expression, show the greatest differential benefit of L
over T. Also, since researchers recently demonstrated
through in-vitro studies that resistance to aromatase
inhibitors is an extremely complex phenomenon, which
does vary between anastrazole, letrozole and exemestane
[15,16], we should be cautious before generalizing these
results to all third-generation aromatase inhibitors.
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